Phathom registers Phase 3 trial testing vonoprazan for episodic heartburn relief in non-erosive GERD
Phathom Pharmaceuticals listed a new Phase 3 study of vonoprazan 10 mg against placebo for heartburn relief in patients with symptomatic non-erosive GERD.
Phathom Pharmaceuticals registered one new clinical trial during the week.
- Phathom Pharmaceuticals listed a Phase 3, randomized, double-blind trial (NCT07752407, sponsor ID NERD-302) comparing vonoprazan 10 mg as needed against placebo for relief of episodic heartburn at 2 hours sustained for 24 hours over 12 weeks of treatment in participants with non-erosive gastroesophageal reflux disease.1 The study is not yet recruiting, with an estimated start date of September 25, 2026, and estimated enrollment of 500 participants.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.